Skip to main content

Table 3 Experimental interventions: study details

From: Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic

Experimental intervention Data source§ Study ID# Study Title Study acronym 
ABX464 AIFA website 2020-001673-75 A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged ≥ 65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study). MiR-AGE
Acalabrutinib AIFA website 2020-001644-25 A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 ACE-ID-201
ACE inhibitors AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Acetylsalicyclic acid AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
ClinicalTrials.gov NCT04808895 Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19 Asperum
Alteplase ClinicalTrials.gov NCT04640194 A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19 TRISTARDS 
Anakinra AIFA website 2020-001167-93 A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101) Sobi.IMMUNO-101
AIFA website 2020-005828-11 Supar-guided anakinra treatment for validation of the risk and early management of severe respiratory failure by covid-19: the save-more double-blind, randomized, phase iii confirmatory trial SAVE-MORE
AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP 
Angiotensin receptor blockers AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
AZD7442 AIFA website 2020-005315-44 A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults TACKLE Study
Baricitinib AIFA website 2020-001955-42 BARICIVID-19 STUDY: MultiCentre, randomised, Phase IIa clinical trial evaluating efficacy and tolerability of Baricitinib as add-on treatment of in-patients with COVID-19 compared to standard therapy BARCIVID
AIFA website 2020-001854-23 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 AMMURAVID
AIFA website 2020-001517-21 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection COV-BARRIER
AIFA website 2020-001185-11 A proof-of concept study of the use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia BREATH trial
ClinicalTrials.gov NCT04358614 Baricitinib Therapy in COVID-19 HPrato-4
Bevacizumab Clincaltrials.gov NCT04275414 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia BEST-CP
Canakinumab AIFA website 2020-001370-30 Phase 3 multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID) CAN-COVID
AIFA website 2020-001854-23 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 AMMURAVID
Chloroquine AIFA website 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care SOLIDARITY
Cholecalciferol AIFA website 2020-002119-23 COVitaminD Trial: prevenzione di complicanze da COVID-19 in pazienti oncologici in trattamento attivo COVitaminD
Clopidogrel AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Colchicine AIFA website 2020-001475-33 Treatment with COLchicine of patients affected by COLVID-19 : a Pilot Study COLVID-19
AIFA website 2020-001258-23 Colchicine To Counteract Inflammatory Response In Covid-19 Pneumonia ColCOVID
AIFA website 2020-001806-42 ColcHicine in patients with COVID-19: a home CarE study CHOICE-19
AIFA website 2020-002234-32 Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19) CONVINCE
Convalescent plasma ClinicalTrials.gov NCT04385043 Hyperimmune Plasma in Patients With COVID-19 Severe Infection COV2-CP
ClinicalTrials.gov  NCT04428021 Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure PLACO-COVID
ClinicalTrials.gov NCT04321421 Hyperimmune Plasma for Critical Patients With COVID-19 COV19-PLASMA
ClinicalTrials.gov NCT04346589 Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients  
ClinicalTrials.gov NCT04393727 Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 TSUNAMI
ClinicalTrials.gov NCT04418531 Convalescent Antibodies Infusion in COVID 19 Patients  
ClinicalTrials.gov NCT04374526 Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. LIFESAVER
ClinicalTrials.gov NCT04569188 Convalescent Plasma in COVID-19 Elderly Patients RESCUE
ClinicalTrials.gov NCT04614012 Hyperimmune Plasma for Patients With COVID-19 IMMUNO-COVID19
ClinicalTrials.gov NCT04622826 plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients  
ClinicalTrials.gov NCT04721236 Early Use of Hyperimmune Plasma in COVID-19 COV-II-PLA
ClinicalTrials.gov NCT04716556 TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients  
COVID-eVax AIFA website 2020-003734-20 A Phase I/Ii Study To Assess The Safety And Immunogenicity Of Covid-Evax, A Candidate Plasmid Dna Vaccine For Covid-19, In Healthy Adult Volunteers COVID-eVax
CPI-006 ClinicalTrials.gov NCT04734873 CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients  
CT-P59 AIFA website 2020-003401-60 A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS-CoV-2 Infection CT-P59 ospedalizzati
AIFA website 2020-003369-20  CT-P59A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection. - CELLTRION CT-P59 non ospedalizzati
Cyclosporin-A AIFA website 2020-003505-58 A proof-of-concept study of the use of Inhaled liposomal -Cyclosporin-A in the treatment of moderate COVID-19-related pneumonia: a two-step phase II clinical trial INCIPIT
Dalteparin  AIFA website 2020-004285-19 A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 ACTIVE4
Darunavir/cobicistat AIFA website 2020-001528-32 Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) ARCO
DAS181 ClinicalTrials.gov NCT04354389 DAS181 for STOP COVID-19  
Defibrotide AIFA website 2020-001513-20 Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia DEF-IVID19
Edoxaban AIFA website 2020-002234-32 Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19) CONVINCE
Emapalumab AIFA website 2020-001167-93 A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101) Sobi.IMMUNO-101
Enoxaparin AIFA website 2020-001708-41 Enoxaparina for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40mg o.d. versus 40mg b.i.d. A randomized Clinical Trial  X-COVID 
AIFA website 2020-001972-13 Randomised controlled trial comparing efficacy and safety of high versus low Low- Molecular Weight Heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD) COVID-19 HD 
AIFA website 2020-001308-40 Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOVID19 INHIXACOVID
AIFA website 2020-002214-40 EMOS-COVID - Enoxaparina EMOS-COVID
AIFA website 2020-004285-19 A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 ACTIVE4
AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Enoxaparin+Methylprednisolone AIFA website 2020-001921-30 Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. STAUNCH
Favipiravir AIFA website 2020-001528-32 Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) ARCO
AIFA website 2020-001115-25 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Inpatients with COVID-19-General Type (HS216C17 HS216C17
Fondaparin AIFA website 2020-004285-19 A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 ACTIVE4
GRAd-COV2 AIFA website 2020-002835-31 A Phase 1, Dose-Escalation Study to assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects RT-CoV-2
AIFA website 2020-005915-39 A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older. COVITAR COVITAR
Heparin AIFA website 2020-004285-19 A Multicenter Adaptive  Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 ACTIVE4
AIFA website  2015-002340-14  Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Heparin+Methylprednisolone AIFA website 2020-001921-30 Steroids and unfractionated heparin in critically ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. STAUNCH
Hydroxycloroquine AIFA website 2020-001441-39 Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) COP-COV
AIFA website  2020-001987-28 PRECOV  Idrossiclorochina negli operatori sanitari PRECOV
AIFA website 2020-001501-24 PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19) PROTECT
AIFA website 2020-001558-23 Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial) Hydro-Stop
AIFA website 2020-001528-32 Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) ARCO
AIFA website 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care SOLIDARITY
Hydroxycloroquine+Azitromycin AIFA website 2020-001802-50  AZI-RCT-COVID-19 - Studio sull'utilizzo di idrossiclorochina+azitromicina AZI-RCT-COVID-19
hzVSF-v13 AIFA website 2020-003614-13 Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled study  hzVSF_v13-0006
Interferon beta-1a  AIFA website 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care SOLIDARITY
AIFA website 2020-002458-25 Randomized, controlled, open label, phase 2 clinical trial of Interferon-β-1a (IFNβ-1a) in COVID-19 patients. INTERCOP
AIFA website 2020-003872-42 Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients ANTIICIPATE
AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Ivermectin AIFA website 2020-002283-32 Randomized, Double-blind, Multi entre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19 COVER
Lopinavir/Ritonavir AIFA website  2020-001528-32 Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study) ARCO
AIFA website 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care SOLIDARITY
MAD0004J08 AIFA website 2020-005469-15  COVID-19: A Phase I dose-escalation study to evaluate the safty and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody MAD0004j08 in healthy adultse MAD0004J08
Mavrilimumab AIFA website 2020-001795-15 A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyper-inflammation: the COMBAT-19 trial  COMBAT-19 
Methyilprednisolone AIFA website 2020-001854-23 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 AMMURAVID
AIFA website 2020-004323-16 Uno studio randomizzato multicentrico in doppio cieco  per valutare l'efficacia della somministrazione di Metilprednisolone ad alte dosi in aggiunta al trattamento standard  in pazienti affetti da polmonite da SARS-CoV2 - Codice: RCT-MP-COVID-19 RCT-MP-COVID-19
ClinicalTrials.gov NCT04636671 Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT) MEDAS
MK-4482 AIFA website 2020-003367-26 A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 MK-4482 ospedalizzati
AIFA website 2020-003368-24 “A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Participants ≥18 Years of Age with COVID-19” MK-4482 non ospedalizzati
Nafamostat Mesylate ClinicalTrials.gov NCT04352400 Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) RACONA
Opaganib AIFA website 2020-002677-95 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia ABC-201
Oxytocin  ClinicalTrials.gov  NCT04386447 Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 OsCOVID19
Pamrevlumab AIFA website 2020-001472-14 An Open-Label, Randomized, Parallel-Arm Study Investigating The Efficacy And Safety Of Intravenous Administration Of Pamrevlumab Versus Standard Of Care In Patients With Covid-19 FibroCov
Plitidepsin ClinicalTrials.gov NCT04784559 Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection Neptuno
Prasugrel AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
ClinicalTrials.gov NCT04445623 Prasugrel in Severe COVID-19 Pneumonia PARTISAN
Polyvalent immunoglobulins AIFA website 2020-002058-26  High dose intravenous polyvalent immunoglobulin (IVIG) in patients with early inflammatory COVID-19. IVIG/H/Covid-19
Raloxifene AIFA website 2020-003936-25 Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID- 19 patients. RLX0120
Ravulizumab AIFA website 2020-001497-30 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome ALXN1210-COV-305
Remdesivir AIFA website  2020-000842-32  A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study) GS-US-540-5774
AIFA website 2020-000841-15 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)  GS-US-540-5773
AIFA website 2020-001366-11 An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care SOLIDARITY
AIFA website 2020-001803-17 A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 (GS-US-540-5823) GS-US-540-5823
Reparixin AIFA website 2020-001645-40 Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19) REPAVID-19 
AIFA website 2020-005919-51 Studio di fase 3, multicentrico, randomizzato, controllato con placebo, sull'efficacia e la sicurezza di Reparixin nel trattamento di pazienti ospedalizzati con polmonite grave da COVID-19  REPAVID-19 Phase 3
Ruxolitinib AIFA website 2020-001662-11 Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19) RUXCOVID
Sarilumab AIFA website 2020-001390-76 ESCAPE Studio di fase 2 sull'utilizzo di sarilumab ESCAPE
AIFA website 2020-001162-12 An adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19). Sarilumab COVID-19
AIFA website 2020-001854-23 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 AMMURAVID*
AIFA website 2020-001745-40 Pilot study on the use of sarilumab in patients with covid-19 infection (COVID-SARI) COVID-SARI
AIFA website  2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Selinexor AIFA website 2020-001411-25 A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001) XPORT-CoV-1001
Siltuximab AIFA website 2020-001854-23 Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 AMMURAVID
Simvastatin AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Sitagliptin ClinicalTrials.gov NCT04365517 The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients SIDIACO
Ticagrelor AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
Tinzaparin AIFA website 2020-004285-19 A Multicenter Adaptive Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 ACTIVE4
Tirofiban  ClinicalTrials.gov NCT04368377 Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19 PIC-19
Tocilizumab AIFA website 2020-001110-38 Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19) TOCIVID-19
AIFA website 2020-001386-37 RCT-TCZ-COVID-19 somministrazione precoce del Tocilizumab RCT-TCZ-COVID-19
AIFA website 2020-001154-22 A randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22) Tocilizumab 2020-001154-22
AIFA website 2020-001854-23 AMMURAVID Studio di fase 3 multiarm della SIMIT AMMURAVID
AIFA website 2020-005291-35 A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids (Anticipant Study)  ANTICIPANT Study
AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
ClinicalTrials.gov NCT04315480 Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis  
Tofacitinib AIFA website 2020-002035-30 TOFAcitinib plus Hydroxycloroquine vs Hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial TOFACOV-2
ClinicalTrials.gov NCT04332042 TOFAcitinib in SARS-CoV2 Pneumonia  TOFACOV 
Vitamin C   AIFA website 2015-002340-14 Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP
ClinicalTrials.gov NCT04323514 Use of Ascorbic Acid in Patients With COVID 19  
  1. Experimental interventions investigated in COVID-19 interventional clinical trials planned to be carried out in Italy (update: 6 April 2021)
  2. §AIFA website (14); ClinicalTrials.gov [16]
  3. #Study ID is EudraCT Number for study from AIFA website and NCT Number for study from ClinicalTrials.gov website
  4. *For the study AMMURAVID, the experimental intervention Sarilumab was retrieved from the protocol v3, 17 April 2020